# EDGAR Filing Document

**Accession Number:** 0001580149
**File Stem:** 0001104659-25-064301
**Filing Date:** 2025-6
**Character Count:** 14192
**Document Hash:** fb444ef5e853457b0d3bec3ba2a91e8c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-064301.hdr.sgml**: 20250630

**ACCESSION NUMBER**: 0001104659-25-064301

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250630

**DATE AS OF CHANGE**: 20250630

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BIOVIE INC.
- **CENTRAL INDEX KEY:** 0001580149
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 462510769
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-90544
- **FILM NUMBER:** 251093870

**BUSINESS ADDRESS:**
- **STREET 1:** 680 W NYE LANE
- **STREET 2:** SUITE 201
- **CITY:** CARSON CITY
- **STATE:** NV
- **ZIP:** 89703
- **BUSINESS PHONE:** 775-888-3162

**MAIL ADDRESS:**
- **STREET 1:** 680 W NYE LANE
- **STREET 2:** SUITE 201
- **CITY:** CARSON CITY
- **STATE:** NV
- **ZIP:** 89703

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NANOANTIBIOTICS, INC.
- **DATE OF NAME CHANGE:** 20130625
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Acuitas Group Holdings, LLC
- **CENTRAL INDEX KEY:** 0001797168

**ORGANIZATION NAME:**
- **EIN:** 270901060
- **STATE OF INCORPORATION:** CA

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 2120 COLORADO AVENUE, #230
- **CITY:** SANTA MONICA
- **STATE:** CA
- **ZIP:** 90404
- **BUSINESS PHONE:** 310-444-4321

**MAIL ADDRESS:**
- **STREET 1:** 2120 COLORADO AVENUE, #230
- **CITY:** SANTA MONICA
- **STATE:** CA
- **ZIP:** 90404

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 11)**

**BIOVIE INC.**

*(Name of Issuer)*

**Class A Common Stock, par value $0.0001 per share**

*(Title of Class of Securities)*

**09074F405**

*(CUSIP Number)*

**Terren S. Peizer**<br>200 Dorado Beach Drive #3831<br>Dorado PR 00646<br>310-444-4321

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**06/25/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **09074F405** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**ACUITAS GROUP HOLDINGS, LLC** | Name of reporting person<br>**ACUITAS GROUP HOLDINGS, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CALIFORNIA** | Citizenship or place of organization<br>**CALIFORNIA** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**3043574.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**3043574.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**3043574.00** | Aggregate amount beneficially owned by each reporting person<br>**3043574.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**15.8%** | Percent of class represented by amount in Row (11)<br>**15.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** + Unless stated otherwise, all share amounts, exercise and conversion prices and similar amounts herein reflect and give effect to the Company's 1:10 reverse stock split, effective on August 6, 2024 (the "August 2024 Reverse Stock Split"), as described in Item 5 below.

* Based on 19,297,999 shares of Common Stock deemed outstanding pursuant to Rule 13d-3(d)(1), calculated as the sum of (i) 18,570,726 shares of Common Stock outstanding as of June 2, 2025, as reported by the Issuer in the Definitive Proxy Statement with respect to its Special Meeting of Stockholders filed with the SEC on June 2, 2025 (the "FY25 DEF14A"), and (ii) 727,273 shares of Common Stock issuable to Acuitas upon exercise of a warrant previously issued to Acuitas in July 2022 (the "Warrant").

| **CUSIP No.** | **09074F405** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**TERREN S. PEIZER** | Name of reporting person<br>**TERREN S. PEIZER** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[x] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[x] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**3050394.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**3050394.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**3050394.00** | Aggregate amount beneficially owned by each reporting person<br>**3050394.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**15.8%** | Percent of class represented by amount in Row (11)<br>**15.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** + Unless stated otherwise, all share amounts, exercise and conversion prices and similar amounts herein reflect and give effect to the August 2024 Reverse Stock Split, effective on August 6, 2024, as described in Item 5 below.

* Based on 19,304,499 shares of Common Stock deemed outstanding pursuant to Rule 13d-3(d)(1), calculated as the sum of (i) 18,570,726 shares of Common Stock outstanding as of June 2, 2025, as reported in the FY25 DEF14A, (ii) 727,273 shares of Common Stock issuable to Acuitas upon exercise of the Warrant, and (iii) an aggregate of 6,500 shares of Common Stock underlying options previously granted to Mr. Peizer, which options automatically became fully vested and exercisable as of March 2, 2023 (the "Options").

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Class A Common Stock, par value $0.0001 per share

**(b) Name of Issuer:**
BIOVIE INC.

**(c) Address of Issuer's Principal Executive Offices:**
680 W NYE LANE, SUITE 201, CARSON CITY, NV, 89703

This Amendment No. 11 to Schedule 13D (this "Amendment") amends and supplements the Schedule 13D previously filed by Acuitas Group Holdings, LLC, a California limited liability company ("Acuitas"), and Terren S. Peizer ("Mr. Peizer" and, together with Acuitas, the "Reporting Persons") on July 3, 2018, as amended by Amendment No. 1 filed on September 25, 2019, Amendment No. 2 filed on September 23, 2020, Amendment No. 3 filed on April 27, 2021, Amendment No. 4 filed on May 10, 2021, Amendment No. 5 filed on June 11, 2021, Amendment No. 6 filed on July 15, 2022, Amendment No. 7 to Schedule 13D filed on August 16, 2022, Amendment No. 8 to Schedule 13D filed on March 7, 2023, Amendment No. 9 to Schedule 13D filed on March 10, 2023 and Amendment No. 10 to Schedule 13D filed on June 21, 2024 (as so amended, the "Original Statement" and, as amended and supplemented by this Amendment, the "Statement"), relating to the Class A common stock, par value $0.0001 per share ("Common Stock"), of BioVie Inc., a Nevada corporation (the "Company" or "Issuer").  Except as specifically amended by this Amendment, items in the Original Statement are unchanged.  Capitalized terms used herein that are not defined have the meaning ascribed to them in the Original Statement.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Items 5(a) and (b) of the Statement are hereby amended and restated as follows:

"(a) and (b)

Except as otherwise expressly set forth in this Amendment, all amount of Shares, as well as the various exercise prices, conversion prices and similar amounts, reported in this Statement, reflect and give effect to the Company's 1:10 reverse stock split, effective on August 6, 2024 (the "August 2024 Reverse Stock Split"). For the avoidance of doubt, none of the amounts of Shares, or exercise prices, conversion prices and similar amounts, reported in this Statement, reflect and give effect to the Company's 1:10 reverse stock split that will become effective on 12:01 a.m., Eastern Time, on July 7, 2025, as reported by the Company on the Current Report on Form 8-K filed with the SEC on June 27, 2025.

Acuitas

All percentages of shares of Common Stock contained herein with respect to Acuitas are based on 19,297,999 shares of Common Stock deemed outstanding pursuant to Rule 13d-3(d)(1), calculated as the sum of (i) 18,570,726 shares of Common Stock outstanding as of June 2, 2025, as reported by the Issuer in the Definitive Proxy Statement with respect to its Special Meeting of Stockholders filed with the SEC on June 2, 2025 (the "FY25 DEF14A"), and (ii) 727,273 shares of Common Stock issuable to Acuitas upon exercise of a warrant previously issued to Acuitas in July 2022 (the "Warrant").

As of the date hereof, Acuitas may be deemed to have beneficial ownership of 3,043,574 shares of Common Stock, consisting of (i) an aggregate of 2,316,301 shares of Common Stock held directly by Acuitas and (ii) 727,273 shares of Common Stock issuable to Acuitas upon exercise of the Warrant.

The shares of Common Stock beneficially owned by Acuitas represents approximately 15.8% of the total number of shares of Common Stock deemed outstanding. Acuitas may be deemed to share the power to vote or direct the vote and dispose or direct the disposition of all 3,043,574 shares of Common Stock with Mr. Peizer.

Mr. Peizer

All percentages of shares of Common Stock contained herein with respect to Mr. Peizer are based on 19,304,499 shares of Common Stock deemed outstanding pursuant to Rule 13d-3(d)(1), calculated as the sum of (i) 18,570,726 shares of Common Stock outstanding as of June 2, 2025, as reported in the FY25 DEF14A, (ii) 727,273 shares of Common Stock issuable to Acuitas upon exercise of the Warrant, and (iii) an aggregate of 6,500 shares of Common Stock underlying options previously granted to Mr. Peizer, which options automatically became fully vested and exercisable as of March 2, 2023 (the "Options").

As of the date hereof, Mr. Peizer may be deemed to have beneficial ownership of 3,050,394 shares of Common Stock, consisting of (i) an aggregate of 2,316,301 shares of Common Stock held directly by Acuitas, (ii) an aggregate of 320 shares of Common Stock held directly by Mr. Peizer, (iii) 727,273 shares of Common Stock issuable to Acuitas upon exercise of the Warrant, and (iv) an aggregate of 6,500 shares of Common Stock underlying the Options.

The shares of Common Stock beneficially owned by Mr. Peizer represents approximately 15.8% of the total number of shares of Common Stock deemed outstanding. Mr. Peizer may be deemed to have the sole power to vote or direct the vote and dispose or direct the disposition of all 3,050,934 shares of Common Stock."

**(b)**
"The shares of Common Stock beneficially owned by Acuitas represents approximately 15.8% of the total number of shares of Common Stock deemed outstanding. Acuitas may be deemed to share the power to vote or direct the vote and dispose or direct the disposition of all 3,043,574 shares of Common Stock with Mr. Peizer.

The shares of Common Stock beneficially owned by Mr. Peizer represents approximately 15.8% of the total number of shares of Common Stock deemed outstanding. Mr. Peizer may be deemed to have the sole power to vote or direct the vote and dispose or direct the disposition of all 3,050,934 shares of Common Stock."

**(c)**
Item 5(c) of the Statement is hereby supplemented with the following:

"The Reporting Persons had no transactions in the securities of the Company during the past sixty days."

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** ACUITAS GROUP HOLDINGS, LLC

**Signature:** /s/ Terren S. Peizer

**Name/Title:** TERREN S. PEIZER, CHAIRMAN

**Date:** 06/30/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** TERREN S. PEIZER

**Signature:** /s/ Terren S. Peizer

**Name/Title:** TERREN S. PEIZER

**Date:** 06/30/2025